ClinicalTrials.gg
CompletedNCT03988608Updated Dec 30, 2025Results posted

Study Assessed the Safety and Efficacy of Eltrombopag in Chinese Refractory or Relapsed Severe Aplastic Anemia (SAA) Subjects.

A Phase 2 interventional study of Eltrombopag in Aplastic Anemia, sponsored by Novartis Pharmaceuticals. Completed at 5 sites in China. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2025-12-30.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies testing eltrombopag in Anemia, Aplastic — 3 open to participants now, 3 under way, 1 of them phase 3. eltrombopag · Anemia, Aplastic.

Enrollment
12th of 17
20 · median 36
Started
2019
the only one that year
Phase 2
11 of 17
1 open now
Registered
12th of 17
by date
Lead sponsor
6 of 17
Novartis Pharmaceuticals

Among the 17 studies testing eltrombopag in Anemia, Aplastic, this one is the 12th largest by enrollment, is the only one that started in 2019, is one of 11 in phase 2, and was the 12th registered.

Anemia, Aplastic

372 studies on the registry are indexed under Anemia, Aplastic; 99 are open to participants now.

Browse Anemia, Aplastic studies →

Open to participants now

3 of the 17 studies testing eltrombopag in Anemia, Aplastic are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About eltrombopag

eltrombopag: first FDA approval 2008 (PROMACTA), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 59 Anemia, Aplastic studies recruiting now, 21 (36%) set no upper age limit and 30 (51%) stop at 75 or younger; 38 take children under 18; 5 take healthy volunteers.

This study: 18 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies testing eltrombopag in Anemia, Aplastic, or all of them as a file.
02

Study summary

This was a non-randomized, open-label, phase II study to assess the efficacy and safety of eltrombopag in Chinese subjects with refractory or relapsed severe aplastic anemia (SAA). Treatment with eltrombopag was started at 25 mg/day and increased by 25 mg/day every 2 weeks according to the platelet count up to 150 mg/day. The hematological response rate was assessed at 3, 6 months and 1 year after starting the study treatment (Week 13, 26 and 52).

Read the detailed description

This was a bridging study to support China registration. An estimation strategy rather than a formal hypothesis testing was pursued. Twenty subjects were enrolled into the study.

Treatment with eltrombopag started at 25 mg/day and increased by 25 mg/day every 2 weeks according to the platelet count, up to 150 mg/day. Hematological response rate was assessed at 3, 6 months and 1 year (Week 13, 26 and 52) after starting the study treatment. Subjects in whom the treatment was found to be effective at 6 months continued to receive the treatment. Eltrombopag was discontinued if the treatment was ineffective at 6 months. Subjects discontinued eltrombopag before 6 months if any of the treatment discontinuation criteria was met.

Analysis set for the primary endpoint was Full Analysis Set (FAS) and subjects who discontinue from the study before Week 26 were treated as non-responders in the response analysis. Eltrombopag treatment was provided to subjects who were considered to require continued treatment at Week 26. After Week 26, if all of the hematologic response criteria (i.e., platelet count > 50×109/L, hemoglobin level > 100 g/L without transfusion, and neutrophil count > 1.0×109/L) remained fulfilled for more than 8 weeks, the dose of eltrombopag was decreased by half. If the response continued for further 8 weeks even at the decreased dose, the treatment was discontinued. If a decrease in any of the hematologic values (i.e., platelet count \< 30×109/L, hemoglobin \< 90 g/L, or neutrophil count \< 0.5×109/L) was found after dose reduction, the dose was increased to the previous level. Furthermore, after treatment interruption, the treatment was restarted if any of the hematologic values decreased to the above-mentioned levels. The response assessment and safety evaluation were performed at Week 52.

The Extension part of this study started 1 year (Week 52) after the initiation of study treatment. This part was included in the study with an ethical consideration for subjects who required continued treatment. The continued treatment was provided up to the launch of eltrombopag after approval. Follow-up visit was performed 30 days after the discontinuation of eltrombopag treatment.

To better understand the pharmacokinetics (PK) characteristics of eltrombopag in Chinese severe aplastic anemia (SAA) patient population, intensive PK blood samples were collected only in the initial 12 Chinese subjects receiving 25 mg/day dose after reaching steady-state, to provide evaluable full PK profiles. Steady-state trough concentrations were collected at other dose levels and in other subjects.

03

Conditions studied

  • Aplastic Anemia

Browse trials for

Keywords

  • Severe Aplastic Anemia
  • Eltrombopag
  • ETB115
  • Chinese subject
  • Chinese refractory or relapsed SAA subjects
  • refractory severe aplastic anemia
  • relapsed severe aplastic anemia
04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Chinese patients aged greater than or equal to 18 years old.
  • Patient with a previous diagnosis of severe aplastic anemia and had insufficient response following at least one treatment course in the period time of > 6 months of with a regimen containing anti-thymocyte globulin (ATG), anti-lymphocyte globulin (ALG), and/or cyclophosphamide, or alemtuzumab.
  • count ≤ 30 × 10\^9/L at screening.
  • Patient must not currently have the option of stem cell transplantation.
  • Patient has an (ECOG) performance status 0-2.
  • Patient with (Fridericia's QT correction formula) at screening \<450 msec, or \<480 msec with bundle branch block, as determined via the mean of a triplicate and assessed at site.

Exclusion criteria

Exclusion Criteria:

  • Treatment with ATG/ALG, cyclophosphamide or alemtuzumab in the past 6 months.
  • Congenital aplastic anemia
  • or ALT ≥3 times the .
  • Creatinine, total , and alkaline phosphatase (ALP) ≥ 1.5× local ULN (total bilirubin ≥ 2.5 × local ULN with Gilbert's Syndrome).
  • Paroxysmal nocturnal hemoglobinuria (PNH) granulocyte clone size determined by flow cytometry ≥ 50%.
  • Presence of chromosomal aberration (-7/7q- detected by fluorescence in situ hybridization (FISH), or other aberrations detected by G-band staining).
  • Evidence of a clonal hematologic bone marrow disorder on cytogenetics.
  • Past medical history of thromboembolism within 6 months or current use of anticoagulants.
  • Have any concomitant and must be fully recovered from treatment for any other malignancy and have been disease-free for 5 years.
  • Patient with (of such severity that it would preclude the patient's ability to consent, be compliant with study procedures, tolerate protocol therapy) bacterial, fungal, mycobacterial, parasitic or viral infection (Patient with acute bacterial infections requiring antibiotic use should delay Screening/enrollment until the course of antibiotic therapy has been completed).
  • Patient with known hepatocellular disease
  • Presences of surface antigen (HBsAg), positive antibody test result at screening.
  • Cardiac disorder () functional classification Grade II/III/IV
  • Past medical history of immediate or delayed to compounds chemically similar to eltrombopag or their .
  • Treatment with another product within 30 days.
  • Prior treatment with eltrombopag, romiplostim, or any other TPO (thrombopoietin) receptor agonist.
  • Positive result for (Human Immunodeficiency Virus) antibody test.
  • Pregnant or nursing (lactating) woman.
  • Woman of .
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    Eltrombopag

    Subjects started eltrombopag treatment at 25 mg/day since Day 1.

    Drug: Eltrombopag

Interventions

  • Eltrombopag are film-coated tablets containing 25 mg of eltrombopag free acid in each tablet.

    Also known as: ETB115

06

What researchers measure

Primary outcomes

  1. Hematologic Response Rate at 6 Months (Week 26) by Investigator

    Hematologic response rate: percentage of subjects who met any of the International Working Group criteria: Platelet count: If platelet transfusion independent at baseline (BL): Transfusion independent and increase from BL by 20×10\^9/L or more; If platelet transfusion dependent at BL: No platelet transfusion requirement for 8 weeks; Hemoglobin: If red blood cells (RBC) transfusion independent at BL: transfusion independent and increase from BL by 15 g/L or more; If RBC transfusion dependent at BL: A decrease of at least 4 units in RBC transfusions in the post-treatment 8-week period (1 unit = RBC derived from 200 mL blood) or no RBC transfusion requirement for 8 weeks; Neutrophil count: In the absence of granulocyte colony stimulating factor (G-CSF) taken within 21 days preceding the blood sample collection: Increase from BL by 0.5×10\^9/L or more, or (if \< 0.5×10\^9/L at BL) increase by 100% or more. Patients who discontinued from the trial before week 26 were treated as non-responders.

    Time frame: 6 months (Week 26)

Secondary outcomes

  1. Hematologic Response Rate by Investigator

    Hematologic response rate: percentage of subjects who met any of the International Working Group criteria: Platelet count: If platelet transfusion independent at baseline (BL): Transfusion independent and increase from BL by 20×10\^9/L or more; If platelet transfusion dependent at BL: No platelet transfusion requirement for 8 wks; Hemoglobin: If red blood cells (RBC) transfusion independent at BL: transfusion independent and increase from BL by 15 g/L or more; If RBC transfusion dependent at BL: A decrease of at least 4 units in RBC transfusions in the post-treatment 8-week period (1 unit =RBC derived from 200 mL blood) or no RBC transfusion requirement for 8 wks; Neutrophil count: In the absence of granulocyte colony stimulating factor (G-CSF) taken within 21 days preceding the blood sample collection: Increase from BL by 0.5×10\^9/L or more, or (if \< 0.5×10\^9/L at BL) increase by 100% or more. Patients who discontinued from the trial before wks 13 \& 26 were treated as non-responders.

    Time frame: Week (Wk) 13, Week 52

  2. Change From Baseline in Platelet Count

    Change (increase from baseline) in platelet count (in the absence of platelet transfusion) were calculated according to the lab test results entered into the case report form (CRF) that were summarized at each visit using descriptive statistics. Platelet Count (×109/L) was assessed in hematology test.

    Time frame: Baseline, Week 13, Week 26, Week 52

  3. Change From Baseline in Hemoglobin Levels

    Change (increase from baseline) in hemoglobin (in the absence of red blood cell (RBC) transfusion) were calculated according to the lab test results entered into the CRF that were summarized at each visit using descriptive statistics. Hemoglobin level (g/L) was assessed in hematology test.

    Time frame: Baseline, Week 13, Week 26 and Week 52

  4. Change From Baseline in Neutrophil Count

    Change (increase from baseline) in neutrophil count (in the absence of granulocyte colony stimulating factor (G-CSF) and calculated according to the lab test results entered into the CRF that were summarized at each visit using descriptive statistics). Neutrophil count (×109/L) was assessed in hematology test.

    Time frame: Baseline, Week 13, Week 26 and Week 52

  5. Time to Hematologic Response by Investigator

    Time to hematological response was defined as the time from the date of first study drug administration to the first hematological response. If a participant did not meet hematological response before or at the cutoff date, censoring was performed using the date of last assessment.

    Time frame: Baseline to Week 26

  6. Duration of Hematologic Response by Investigator

    Duration of hematologic response (any response according to the response criteria for the primary endpoint). For subjects who responded, duration of response was defined as the number of weeks from the first date of hematological response until the first date of relapse or death. Only participants with at least two response assessments were included for the duration of hematologic response assessment.

    Time frame: up to approx. 3.5 years

  7. Frequency of Platelets Transfusion

    For subjects receiving transfusion (platelets) at baseline, the frequency of platelet transfusion in each period (Baseline: 4 weeks before Day 1; Week 13, 26, 52: 4 weeks before each visit day) was summarized using descriptive statistics.

    Time frame: Baseline, Week 13, Week 26 and Week 52

  8. Amount of Platelets Transfusion

    The amount of transfusion was defined as the sum of transfusion multiplied by the volume of transfusion.

    Time frame: Baseline, Week 13, Week 26 and Week 52

  9. Frequency of Red Blood Cells (RBC) Transfusion

    For subjects receiving transfusion (RBC (Red Blood Cell)) at baseline, the frequency of RBC transfusion in each period (Baseline: 8 weeks before Day 1; Week 13, 26, 52: 8 weeks before each visit day) was summarized using descriptive statistics.

    Time frame: Baseline, Week 13, Week 26 and Week 52

  10. Amount of Red Blood Cells (RBC) Transfusion

    The amount of RBC transfusion was defined as the sum of transfusion multiplied by the volume of transfusion.

    Time frame: Baseline, Week 13, Week 26 and Week 52

  11. Plasma PK Parameters of Eltrombopag: Cmax

    Cmax is the maximum (peak) observed plasma drug concentration after single dose administration (mass\*volume-1). Blood samples were collected from patients to assess the plasma concentrations of eltrombopag. The plasma concentrations were used to determine the PK characteristics of eltrombopag. Serial intensive PK blood samples were collected for the initial 25 mg/day dose to provide at least 12 participants with evaluable PK profiles at steady state.

    Time frame: pre-dose, and 1, 2, 4, 6, 8 and 24 hours post-dose on Day 14

  12. Plasma PK Parameters of Eltrombopag: Tmax

    Tmax is the time to reach maximum (peak) plasma drug concentration after single dose administration (time). Blood samples were collected from all patients to assess the plasma concentrations of eltrombopag. The plasma concentrations were used to determine the PK characteristics of eltrombopag. Serial intensive PK blood samples were collected for the initial 25 mg/day dose to provide at least 12 participants with evaluable PK profiles at steady state.

    Time frame: pre-dose, and 1, 2, 4, 6, 8 and 24 hours post-dose on Day 14

  13. Plasma PK Parameters of Eltrombopag: AUCtau & AUClast

    AUCtau is the area under the curve calculated to the end of a dosing interval (tau) at steady-state (amount\*time\*volume-1). AUClast is the AUC calculated from time 0 to the time of the last quantifiable concentration. Blood samples were collected from patients to assess the plasma concentrations of eltrombopag. The plasma concentrations were used to determine the PK characteristics of eltrombopag. Serial intensive PK blood samples were collected for the initial 25 mg/day dose to provide at least 12 participants with evaluable PK profiles at steady state.

    Time frame: pre-dose, and 1, 2, 4, 6, 8 and 24 hours post-dose on Day 14

  14. Plasma PK Parameters of Eltrombopag: CLss/F

    Steady State (CLss/F) is the apparent systemic (or total body) clearance at steady state from plasma (volume/time) following drug administration. Blood samples were collected from patients to assess the plasma concentrations of eltrombopag. The plasma concentrations were used to determine the PK characteristics of eltrombopag. Serial intensive PK blood samples were collected for the initial 25 mg/day dose to provide at least 12 participants with evaluable PK profiles at steady state.

    Time frame: pre-dose, and 1, 2, 4, 6, 8 and 24 hours post-dose on Day 14

  15. Plasma Trough Concentration of Eltrombopag

    Ctrough is the pre-dose concentration at the end of dose interval (mass\*volume-1). Blood samples were collected from patients to assess the plasma concentrations of eltrombopag. The plasma concentrations were used to determine the PK characteristics of eltrombopag. Serial intensive PK blood samples were collected for the initial 25 mg/day dose to provide at least 12 participants with evaluable PK profiles at steady state. Sparse PK blood samples were collected for the other doses and in the rest of the patients for Ctrough assessment.

    Time frame: Pre-dose sample on the 15th day after each new dose level was started

  16. Number of Participants With Clonal Evolution

    Number of participants with clonal evolution with a normal karyotype at baseline including clonal evolution to PNH (Paroxysmal Nocturnal Hemoglobinuria), evolution to AML (Acute Myeloid Leukemia) or MDS (Myelodysplastic Syndromes).

    Time frame: From Baseline up to approx. 2.9 years

07

Results

Posted Feb 3, 2025

Participant flow

The study enrolled all 20 participants from 5 sites in China.

Participant flow — Overall Study
MilestoneEltrombopag
Started20
Completed 26-week treatment phase17
Entered week 52 treatment phase15
Completed week 52 treatment phase14
Completed14
Not completed6
Withdrew: Adverse event1
Withdrew: Lost to follow-up1
Withdrew: Withdrawal by subject3
Withdrew: Death1

Outcome measures

PrimaryHematologic Response Rate at 6 Months (Week 26) by Investigator

Hematologic response rate: percentage of subjects who met any of the International Working Group criteria: Platelet count: If platelet transfusion independent at baseline (BL): Transfusion independent and increase from BL by 20×10\^9/L or more; If platelet transfusion dependent at BL: No platelet transfusion requirement for 8 weeks; Hemoglobin: If red blood cells (RBC) transfusion independent at BL: transfusion independent and increase from BL by 15 g/L or more; If RBC transfusion dependent at BL: A decrease of at least 4 units in RBC transfusions in the post-treatment 8-week period (1 unit = RBC derived from 200 mL blood) or no RBC transfusion requirement for 8 weeks; Neutrophil count: In the absence of granulocyte colony stimulating factor (G-CSF) taken within 21 days preceding the blood sample collection: Increase from BL by 0.5×10\^9/L or more, or (if \< 0.5×10\^9/L at BL) increase by 100% or more. Patients who discontinued from the trial before week 26 were treated as non-responders.

Time frame:
6 months (Week 26)
Reported as:
Number · Percentage of participants
Hematologic Response Rate at 6 Months (Week 26) by Investigator
Percentage of participantsEltrombopag
Hematologic Response Rate at 6 Months (Week 26) by Investigator70.0 (49.2 to 86.0)
SecondaryHematologic Response Rate by Investigator

Hematologic response rate: percentage of subjects who met any of the International Working Group criteria: Platelet count: If platelet transfusion independent at baseline (BL): Transfusion independent and increase from BL by 20×10\^9/L or more; If platelet transfusion dependent at BL: No platelet transfusion requirement for 8 wks; Hemoglobin: If red blood cells (RBC) transfusion independent at BL: transfusion independent and increase from BL by 15 g/L or more; If RBC transfusion dependent at BL: A decrease of at least 4 units in RBC transfusions in the post-treatment 8-week period (1 unit =RBC derived from 200 mL blood) or no RBC transfusion requirement for 8 wks; Neutrophil count: In the absence of granulocyte colony stimulating factor (G-CSF) taken within 21 days preceding the blood sample collection: Increase from BL by 0.5×10\^9/L or more, or (if \< 0.5×10\^9/L at BL) increase by 100% or more. Patients who discontinued from the trial before wks 13 \& 26 were treated as non-responders.

Time frame:
Week (Wk) 13, Week 52
Reported as:
Number · Percentage of participants
Hematologic Response Rate by Investigator
Percentage of participantsEltrombopag
Week 1365.0 (44.2 to 82.3)
Week 5265.0 (44.2 to 82.3)
SecondaryChange From Baseline in Platelet Count

Change (increase from baseline) in platelet count (in the absence of platelet transfusion) were calculated according to the lab test results entered into the case report form (CRF) that were summarized at each visit using descriptive statistics. Platelet Count (×109/L) was assessed in hematology test.

Time frame:
Baseline, Week 13, Week 26, Week 52
Reported as:
Mean · 10^9 platelets/liter
Change From Baseline in Platelet Count
10^9 platelets/literEltrombopag
Baseline (BL)10.725 ± 7.8731
Change from BL at Week 13/Day9210.265 ± 14.1456
Change from BL at Week 26/Day 18326.933 ± 30.5304
Change from BL at Week 52/Day 36541.071 ± 56.6816
SecondaryChange From Baseline in Hemoglobin Levels

Change (increase from baseline) in hemoglobin (in the absence of red blood cell (RBC) transfusion) were calculated according to the lab test results entered into the CRF that were summarized at each visit using descriptive statistics. Hemoglobin level (g/L) was assessed in hematology test.

Time frame:
Baseline, Week 13, Week 26 and Week 52
Reported as:
Mean · gram/liter
Change From Baseline in Hemoglobin Levels
gram/literEltrombopag
Baseline66.9 ± 19.90
Change from BL at Week 13/Day9222.4 ± 23.47
Change from baseline at Week 26/Day 18331.9 ± 29.20
Change from BL at Week 52/Day 36532.9 ± 33.21
SecondaryChange From Baseline in Neutrophil Count

Change (increase from baseline) in neutrophil count (in the absence of granulocyte colony stimulating factor (G-CSF) and calculated according to the lab test results entered into the CRF that were summarized at each visit using descriptive statistics). Neutrophil count (×109/L) was assessed in hematology test.

Time frame:
Baseline, Week 13, Week 26 and Week 52
Reported as:
Mean · 10^9 neutrophils/liter
Change From Baseline in Neutrophil Count
10^9 neutrophils/literEltrombopag
Baseline1.199 ± 1.3483
Change from BL at Week 13/Day 92 (n = 16)-0.160 ± 1.4141
Change from baseline at Week 26/Day 183 (n = 14)0.196 ± 1.6822
Change from BL at Week 52/Day 365 (n = 14)0.447 ± 1.5764
SecondaryTime to Hematologic Response by Investigator

Time to hematological response was defined as the time from the date of first study drug administration to the first hematological response. If a participant did not meet hematological response before or at the cutoff date, censoring was performed using the date of last assessment.

Time frame:
Baseline to Week 26
Reported as:
Median · Weeks
Time to Hematologic Response by Investigator
WeeksEltrombopag
Time to Hematologic Response by Investigator10.0 (8.0 to 12.0)
SecondaryDuration of Hematologic Response by Investigator

Duration of hematologic response (any response according to the response criteria for the primary endpoint). For subjects who responded, duration of response was defined as the number of weeks from the first date of hematological response until the first date of relapse or death. Only participants with at least two response assessments were included for the duration of hematologic response assessment.

Time frame:
up to approx. 3.5 years
Reported as:
Median · Weeks
Duration of Hematologic Response by Investigator
WeeksEltrombopag
Duration of Hematologic Response by InvestigatorNA (22.3 to NA)
SecondaryFrequency of Platelets Transfusion

For subjects receiving transfusion (platelets) at baseline, the frequency of platelet transfusion in each period (Baseline: 4 weeks before Day 1; Week 13, 26, 52: 4 weeks before each visit day) was summarized using descriptive statistics.

Time frame:
Baseline, Week 13, Week 26 and Week 52
Reported as:
Mean · occurrences
Frequency of Platelets Transfusion
occurrencesEltrombopag
Baseline1.8 ± 1.32
Week 130.4 ± 0.88
Week 260.1 ± 0.35
Week 520.0 ± 0.00
SecondaryAmount of Platelets Transfusion

The amount of transfusion was defined as the sum of transfusion multiplied by the volume of transfusion.

Time frame:
Baseline, Week 13, Week 26 and Week 52
Reported as:
Mean · Units
Amount of Platelets Transfusion
UnitsEltrombopag
Baseline3.7 ± 3.63
Week 130.4 ± 0.88
Week 260.1 ± 0.35
Week 520.0 ± 0.00
SecondaryFrequency of Red Blood Cells (RBC) Transfusion

For subjects receiving transfusion (RBC (Red Blood Cell)) at baseline, the frequency of RBC transfusion in each period (Baseline: 8 weeks before Day 1; Week 13, 26, 52: 8 weeks before each visit day) was summarized using descriptive statistics.

Time frame:
Baseline, Week 13, Week 26 and Week 52
Reported as:
Mean · occurrences
Frequency of Red Blood Cells (RBC) Transfusion
occurrencesEltrombopag
Baseline3.0 ± 2.04
Week 131.8 ± 2.83
Week 261.5 ± 2.02
Week 520.5 ± 0.71
SecondaryAmount of Red Blood Cells (RBC) Transfusion

The amount of RBC transfusion was defined as the sum of transfusion multiplied by the volume of transfusion.

Time frame:
Baseline, Week 13, Week 26 and Week 52
Reported as:
Mean · Units
Amount of Red Blood Cells (RBC) Transfusion
UnitsEltrombopag
Baseline6.6 ± 4.16
Week 133.8 ± 6.18
Week 253.0 ± 4.02
Week 521.4 ± 1.90
SecondaryPlasma PK Parameters of Eltrombopag: Cmax

Cmax is the maximum (peak) observed plasma drug concentration after single dose administration (mass\*volume-1). Blood samples were collected from patients to assess the plasma concentrations of eltrombopag. The plasma concentrations were used to determine the PK characteristics of eltrombopag. Serial intensive PK blood samples were collected for the initial 25 mg/day dose to provide at least 12 participants with evaluable PK profiles at steady state.

Time frame:
pre-dose, and 1, 2, 4, 6, 8 and 24 hours post-dose on Day 14
Reported as:
Mean · ng/mL
Plasma PK Parameters of Eltrombopag: Cmax
ng/mLEltrombopag
Plasma PK Parameters of Eltrombopag: Cmax3450 ± 1900
SecondaryPlasma PK Parameters of Eltrombopag: Tmax

Tmax is the time to reach maximum (peak) plasma drug concentration after single dose administration (time). Blood samples were collected from all patients to assess the plasma concentrations of eltrombopag. The plasma concentrations were used to determine the PK characteristics of eltrombopag. Serial intensive PK blood samples were collected for the initial 25 mg/day dose to provide at least 12 participants with evaluable PK profiles at steady state.

Time frame:
pre-dose, and 1, 2, 4, 6, 8 and 24 hours post-dose on Day 14
Reported as:
Median · hour
Plasma PK Parameters of Eltrombopag: Tmax
hourEltrombopag
Plasma PK Parameters of Eltrombopag: Tmax3.73 (0.917 to 5.90)
SecondaryPlasma PK Parameters of Eltrombopag: AUCtau & AUClast

AUCtau is the area under the curve calculated to the end of a dosing interval (tau) at steady-state (amount\*time\*volume-1). AUClast is the AUC calculated from time 0 to the time of the last quantifiable concentration. Blood samples were collected from patients to assess the plasma concentrations of eltrombopag. The plasma concentrations were used to determine the PK characteristics of eltrombopag. Serial intensive PK blood samples were collected for the initial 25 mg/day dose to provide at least 12 participants with evaluable PK profiles at steady state.

Time frame:
pre-dose, and 1, 2, 4, 6, 8 and 24 hours post-dose on Day 14
Reported as:
Mean · h*ng/mL
Plasma PK Parameters of Eltrombopag: AUCtau & AUClast
h*ng/mLEltrombopag
AUCtau67900 ± 31400
AUClast62700 ± 33200
SecondaryPlasma PK Parameters of Eltrombopag: CLss/F

Steady State (CLss/F) is the apparent systemic (or total body) clearance at steady state from plasma (volume/time) following drug administration. Blood samples were collected from patients to assess the plasma concentrations of eltrombopag. The plasma concentrations were used to determine the PK characteristics of eltrombopag. Serial intensive PK blood samples were collected for the initial 25 mg/day dose to provide at least 12 participants with evaluable PK profiles at steady state.

Time frame:
pre-dose, and 1, 2, 4, 6, 8 and 24 hours post-dose on Day 14
Reported as:
Mean · L/h
Plasma PK Parameters of Eltrombopag: CLss/F
L/hEltrombopag
Plasma PK Parameters of Eltrombopag: CLss/F0.441 ± 0.178
SecondaryPlasma Trough Concentration of Eltrombopag

Ctrough is the pre-dose concentration at the end of dose interval (mass\*volume-1). Blood samples were collected from patients to assess the plasma concentrations of eltrombopag. The plasma concentrations were used to determine the PK characteristics of eltrombopag. Serial intensive PK blood samples were collected for the initial 25 mg/day dose to provide at least 12 participants with evaluable PK profiles at steady state. Sparse PK blood samples were collected for the other doses and in the rest of the patients for Ctrough assessment.

Time frame:
Pre-dose sample on the 15th day after each new dose level was started
Reported as:
Mean · ng/mL
Plasma Trough Concentration of Eltrombopag
ng/mLEltrombopag
concentration at 25 mg2180 ± 1490
concentration at 50 mg5180 ± 3320
concentration at 75 mg11300 ± 6000
concentration at 100 mg14700 ± 8070
concentration at 125 mg20300 ± 11300
concentration at 150 mg23800 ± 13700
SecondaryNumber of Participants With Clonal Evolution

Number of participants with clonal evolution with a normal karyotype at baseline including clonal evolution to PNH (Paroxysmal Nocturnal Hemoglobinuria), evolution to AML (Acute Myeloid Leukemia) or MDS (Myelodysplastic Syndromes).

Time frame:
From Baseline up to approx. 2.9 years
Reported as:
Count of participants · Participants
Number of Participants With Clonal Evolution
ParticipantsEltrombopag
Number of Participants With Clonal Evolution2
Post-hocAll Collected Deaths

Deaths were collected from the first dose until end of study, a maximum duration of up to 3.5 years. On-treatment deaths were collected within 30 days of the last dose, while post-treatment deaths were collected more than 30 days after the last dose for those who discontinued treatment early. Adverse events were collected from the first dose until 30 days after the last dose, also up to a maximum duration if 3.5 years. Adverse Events were not collected in the post-treatment period.

Time frame:
On-treatment deaths: up to approx. 3.5 years, post-treatment deaths: up to approx. 3.5 years
Reported as:
Number · Participants
All Collected Deaths
ParticipantsEltrombopag
All Deaths1
On-treatment deaths0
Post-treatment deaths1

Adverse events

Collected over Deaths were collected from the first dose until end of study, a maximum duration of up to 3.5 years. On-treatment deaths were collected within 30 days of the last dose, while post-treatment deaths were collected more than 30 days after the last dose for those who discontinued treatment early. Adverse events were collected from the first dose until 30 days after the last dose, also up to a maximum duration if 3.5 years. Adverse Events were not collected in the post-treatment period.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Eltrombopag (On-treatment)0/20 (0%)8/20 (40%)19/20 (95%)
Eltrombopag (Post-treatment)1/20 (5%)——
Most frequent serious events
Showing 10 of 14
Most frequent serious events
EventEltrombopag (On-treatment)Eltrombopag (Post-treatment)
PneumoniaInfections and infestations3/20—
Upper respiratory tract infectionInfections and infestations2/20—
Intentional product misuseInjury, poisoning and procedural complications2/20—
Febrile neutropeniaBlood and lymphatic system disorders1/20—
GastritisGastrointestinal disorders1/20—
Gastrointestinal haemorrhageGastrointestinal disorders1/20—
PyrexiaGeneral disorders1/20—
Liver injuryHepatobiliary disorders1/20—
Spermatic cord funiculitisInfections and infestations1/20—
Groin painMusculoskeletal and connective tissue disorders1/20—
Most frequent other events
Showing 10 of 29
Most frequent other events
EventEltrombopag (On-treatment)Eltrombopag (Post-treatment)
Upper respiratory tract infectionInfections and infestations8/20—
Blood creatinine increasedInvestigations6/20—
PyrexiaGeneral disorders5/20—
HyperbilirubinaemiaHepatobiliary disorders5/20—
HyperuricaemiaMetabolism and nutrition disorders5/20—
Hepatic function abnormalHepatobiliary disorders4/20—
Blood glucose increasedInvestigations4/20—
HypertriglyceridaemiaMetabolism and nutrition disorders4/20—
Oedema peripheralGeneral disorders3/20—
Liver injuryHepatobiliary disorders3/20—

Baseline characteristics

Full Analysis Set (FAS) comprised all patients to whom study treatment had been assigned and received one dose of study treatment.

Age, Continuous
Age, Continuous(years)Eltrombopag
Mean39.0 ± 13.25
Sex: Female, Male
Sex: Female, Male(Participants)Eltrombopag
Female5
Male15
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Eltrombopag
Asian20
08

Study locations

5 sites
  • Novartis Investigative Site
    Nanjing, Jiangsu 210000, China
  • Novartis Investigative Site
    Nanchang, Jiangxi 330006, China
  • Novartis Investigative Site
    Chengdu, Sichuan 610041, China
  • Novartis Investigative Site
    Tianjin, 300020, China
  • Novartis Investigative Site
    Tianjin, 300052, China
09

References and documents

Publications

  • Chang H, He G, Fu R, Li F, Han B, Li T, Liu L, Mittal H, Jin H, Zhang F. Efficacy and safety of eltrombopag in Chinese patients with refractory or relapsed severe aplastic anemia. Sci Rep. 2023 Nov 2;13(1):18955. doi: 10.1038/s41598-023-45607-0. PubMed 37919313 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent expert panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data is currently available according to the process described on www.clinicalstudydatarequest.com

Data sharing details ↗ · www.clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2019 to primary completion in Jul 2021, 19 months.

Results were first posted in Feb 2025, 3 years 6 months after primary completion.

Of 60 phase 2 interventional studies under Anemia, Aplastic, half reached primary completion within 76 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 104. This study's 19 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 13, 2019
First posted
Jun 17, 2019
StartActual
Dec 9, 2019
Primary completionActual
Jul 16, 2021
CompletionActual
May 17, 2023
Results first posted
Feb 3, 2025
Last update
Dec 30, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 30, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03988608
Responsible party
Sponsor
First posted
Jun 17, 2019
Start date
Dec 9, 2019
Primary completion
Jul 16, 2021
Completion
May 17, 2023
Results posted
Feb 3, 2025
Last update
Dec 30, 2025

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Eltrombopag

Start the discussion